Discover 137 paid clinical trials in Shreveport, Louisiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 137
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
for
Anaplastic Large Cell Lymphoma, ALK-Negative,
Location: Shreveport LA, New Orleans LA, Oklahoma City OK,
Sponsor: Eastern Cooperative Oncology Group
Sex: All
Age: 18 - 70+
Code: NCT06724237
Phase 3, Recruiting
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
for
Parkinson Disease
Location: Shreveport LA, Houston TX, New Orleans LA,
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Sex: All
Age: 18+
Code: NCT06719583
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for
Lymphoma, Large B-Cell, Diffuse
Location: Shreveport LA, Monroe LA, Palestine TX, Hot Springs AR,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06890884
Phase 2, Recruiting
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
for
Head and Neck Squamous Cell Carcinoma,
Location: Shreveport LA
Sponsor: Pure Biologics S.A.
Sex: All
Age: 18+
Code: NCT06700070
Early Phase 1, Recruiting
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors